Toronto, Ontario–(Newsfile Corp. – April 8, 2022) – Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) (“Scryb” or the “Company”), is pleased to announce that it has entered an agreement with a multinational manufacturing corporation that is a Fortune 500 company and an S&P 500 component. The Company will evaluate a Cybeats’ enterprise cybersecurity product suite for a trial deployment period.
Two divisions of the multinational manufacturing firm will trial Cybeats SBOM Studio, which is an enterprise Software Supply Chain Risk Management product that is used for SBOM (Software Bill of Materials) document management, repository, and more. One of the subsidiary entities that is commencing a software evaluation period is a precision measurement device manufacturer, and the other entity is focused on the aerospace industry. The Fortune 500 company manufactures products and provides engineering services for industrial, commercial, and consumer markets.
“When Cybeats enterprise product suites such as SBOM Studio experience interest from multi-billion dollar companies of this magnitude, it is reassuring to us that the market is seeking innovative security solutions that mitigate cyber risks and increase the corporate capabilities surrounding the software supply chain,” said Yoav Raiter, CEO, Scryb.
About SBOM
An SBOM is a record of all software components that make up a product. It is a complete, formally structured list of components, libraries, and modules that are included in the software. An analogy for SBOM is to the nutritional ingredients list found on everyday food products, such as a can of coke. A Coca Cola Ingredient list includes information that can be used to gauge allergy risk, expiry dates and other food safety information. Just as food products are mandated to provide this list to consumers, SBOM is quickly becoming a similar standard in the software industry.
Organizations and governments are growing more aware of the importance of software supply chain security. The Whitehouse signed an executive order in May 2021, for example, stipulating that all vendors responsible for supplying software to federal agencies must provide an SBOM. Many regulations take effect in and around August 2022, and others are to follow thereafter. It is anticipated that SBOM will become a global standard across industries.
Cybeats SBOM Studio gives access to one-of-a-kind tools to manage SBOM needs and software vulnerabilities, and provides proactive mitigation of risks to their software supply chain. Key product features include:
The Company is not making any expressed or explicit claims that the agreement discussed herein has, or will necessarily lead to, commercial engagements that involve financial or commercial revenues for any Cybeats product lines or for Scryb Inc.
RECENT NEWS: Cybeats recently appointed Bob Lyle, cybersecurity industry leader, as Chief Revenue Officer. To read the full story: https://bit.ly/3r8AMTz
About Cybeats
Cybeats delivers intelligent security applications for software supply chains and IoT connected devices, autonomously detecting and eliminating cyber risks from design to operation. Cybeats – Software Made Certain. Website: www.cybeats.com
SUBSCRIBE: For more information, or to SubScryb to the Company’s mail list, visit: http://scryb.ai
About Scryb
Scryb is a platform that powers businesses and technologies with applied intelligence, real-time analytics, and actionable insights. The platform boasts proven adaptability across diverse markets, from digital health and diagnostics to cybersecurity and manufacturing. The cloud-based platform is composed of crucial elements including sensor technology, IoT, predictive analytics, and computer vision.
For more information, please visit our website at: http://scryb.ai
Contact:
W. Clark Kent
President
Office. 647-872-9982
TF. 1-844-247-6633
Email: info@scryb.ai
Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/119783
CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free…
ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…